ALK and neoplasm: For patients without actionable mutations [i.e., epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)], different immune checkpoint inhibitors are recommended in single-agent or dual immunotherapy, or in combination with chemotherapy or bevacizumab, an anti-VEGF antibody, based on PD-L1 expression level on tumor cells3.